The average one-year price target for Krystal Biotech (NasdaqGS:KRYS) has been revised to $269.93 / share. This is an increase of 18.96% from the prior estimate of $226.90 dated December 18, 2025.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $208.06 to a high of $336.00 / share. The average price target represents a decrease of 7.64% from the latest reported closing price of $292.26 / share.
What is the Fund Sentiment?
There are 608 funds or institutions reporting positions in Krystal Biotech. This is an decrease of 48 owner(s) or 7.32% in the last quarter. Average portfolio weight of all funds dedicated to KRYS is 0.23%, an increase of 0.15%. Total shares owned by institutions decreased in the last three months by 0.14% to 33,627K shares. 
The put/call ratio of KRYS is 0.35, indicating a bullish outlook.
What are Other Shareholders Doing?
Avoro Capital Advisors holds 2,778K shares representing 9.58% ownership of the company. In its prior filing, the firm reported owning 2,660K shares , representing an increase of 4.24%. The firm decreased its portfolio allocation in KRYS by 1.01% over the last quarter.
FBIOX - Biotechnology Portfolio holds 1,855K shares representing 6.40% ownership of the company. In its prior filing, the firm reported owning 1,878K shares , representing a decrease of 1.20%. The firm decreased its portfolio allocation in KRYS by 19.07% over the last quarter.
IJR - iShares Core S&P Small-Cap ETF holds 1,515K shares representing 5.22% ownership of the company. In its prior filing, the firm reported owning 1,564K shares , representing a decrease of 3.27%. The firm decreased its portfolio allocation in KRYS by 26.80% over the last quarter.
Soleus Capital Management holds 1,019K shares representing 3.51% ownership of the company. In its prior filing, the firm reported owning 923K shares , representing an increase of 9.41%. The firm increased its portfolio allocation in KRYS by 7.77% over the last quarter.
SMCWX - SMALLCAP WORLD FUND INC holds 887K shares representing 3.06% ownership of the company. No change in the last quarter.
https://www.nasdaq.com/articles/krystal-biotech-krys-price-target-increased-1896-26993
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.